{"timestamp": "2026-01-17T23:04:34.816942", "question": "{\"CASE_CORE\":{\"ADJUVANT_TREATMENT\":{\"cycles_or_courses\":\"Unknown\",\"given\":\"Unknown\",\"regimens\":[]},\"BIOMARKERS\":{\"AFP\":\"Unknown\",\"CA125\":\"Unknown\",\"HER2\":\"ERBB2-\",\"MSI\":\"MSS\",\"PDL1_CPS\":\"Unknown\",\"TMB\":\"TMB-L\"},\"BRCA1\":\"Wildtype\",\"BRCA2\":\"Wildtype\",\"CURRENT_STATUS\":\"Condition stable\",\"DIAGNOSIS\":{\"components\":[\"Krukenberg tumor\",\"粘液腺癌\",\"印戒细胞癌分化\"],\"histology\":\"粘液腺癌，部分为高-中分化，相当一部分为低分化伴印戒细胞癌分化\",\"laterality\":\"Left\",\"primary\":\"Ovarian Krukenberg tumor\",\"site\":\"Ovary\"},\"HRD\":\"Negative\",\"INITIAL_TREATMENT\":\"Yes\",\"LINE_OF_THERAPY\":[],\"MAINTENANCE\":\"Unknown\",\"MAINTENANCE_DETAIL\":{\"end_date\":\"Unknown\",\"given\":\"Unknown\",\"regimens\":[],\"start_date\":\"Unknown\"},\"NEOADJUVANT\":\"Unknown\",\"PFI_days\":\"Unknown\",\"PLATINUM_HISTORY\":[],\"PLATINUM_PFI_CURRENT\":\"Unknown\",\"PLATINUM_STATUS\":\"Unknown\",\"PLATINUM_STATUS_CURRENT\":\"Unknown\",\"RELAPSE\":\"Yes\",\"RELAPSE_DATE\":{\"date\":\"2025-01-20\",\"evidence\":\"Head MRI showing a metastasis in a cerebral sulcus\",\"type\":\"Radiologic\"},\"STAGE\":{\"stage_basis\":\"Unknown\",\"stage_system\":\"Unknown\",\"stage_text\":\"Unknown\"},\"SURGERY_DONE\":{\"date\":\"2024-12-20\",\"performed\":\"Yes\",\"procedure\":\"Laparoscopy converted to laparotomy: uterus with bilateral adnexa resection, omentectomy, para-aortic LN dissection, diaphragm lesion resection, left ureter and peri-tumor resection, left ureteral stent, ureteroneocystostomy\"},\"VISIT_DATE\":\"2025-04-03\",\"first_relapse_date\":\"2025-01-20\",\"last_platinum_end_date\":\"Unknown\"},\"LAB_TRENDS\":{\"labs\":[{\"analyte\":\"Cr\",\"history\":[{\"date\":\"2025-02-10\",\"flag\":\"↑\",\"value\":\"258.9\"},{\"date\":\"2025-02-12\",\"flag\":\"↓\",\"value\":\"170\"},{\"date\":\"Unknown\",\"flag\":\"↓\",\"value\":\"110\"}],\"latest\":{\"date\":\"Unknown\",\"flag\":\"↓\",\"value\":\"110\"},\"reference_range\":\"Unknown\",\"unit\":\"umol/L\"}],\"milestones\":[{\"date\":\"2024-12-20\",\"description\":\"Primary cytoreductive surgery with multiple resections\",\"type\":\"Surgery\"},{\"date\":\"2025-02-12\",\"description\":\"Ureteroscopy and bilateral stent placement (postop Cr decreased)\",\"type\":\"Other\"},{\"date\":\"2025-02-15\",\"description\":\"Left nephrostomy performed\",\"type\":\"Other\"}]},\"MED_ONC\":{\"current_regimen\":{\"cycle_info\":\"Unknown\",\"last_admin_date\":\"Unknown\",\"name\":\"Unknown\"},\"genetic_testing\":{\"germline\":[\"HRD: Negative\",\"BRCA1: Wildtype\",\"BRCA2: Wildtype\"],\"somatic\":[\"HRD: Negative\",\"BRCA1: Wildtype\",\"BRCA2: Wildtype\"]},\"monitoring_points\":[],\"planned_next_regimen\":\"Unknown\",\"prior_systemic_therapies\":[]},\"NUC_MED\":{\"studies\":[]},\"PATHOLOGY\":{\"specimens\":[{\"components\":[\"粘液腺癌\",\"印戒细胞癌分化\"],\"date\":\"2024-12-20\",\"diagnosis\":\"左附件krukenberg瘤，粘液腺癌，部分为高-中分化，相当一部分为低分化伴印戒细胞癌分化。子宫肌壁全层见癌组织浸润，输尿管见癌组织浸润，膈肌转移结节阳性，送检淋巴结见癌转移。IHC:ER/PR-\",\"grade\":\"Mixed high-intermediate and low differentiation\",\"ihc\":[{\"marker\":\"ER/PR\",\"result\":\"-\"}],\"involvement_sites\":[\"Uterine myometrium full-thickness\",\"Ureter\",\"Diaphragm\",\"Lymph nodes\"],\"laterality\":\"Left\",\"molecular\":[{\"result\":\"TMB-L, MSS, FBXW7 R505C; KNB-, BRCA-, ERBB2-, NTRK-, FGFR2-\",\"test\":\"Genomic panel\"}],\"raw_text\":\"左附件krukenberg瘤，粘液腺癌，部分为高-中分化，相当一部分为低分化伴印戒细胞癌分化。子宫肌壁全层见癌组织浸润，输尿管见癌组织浸润，膈肌转移结节阳性，送检淋巴结见癌转移。IHC:ER/PR-。外院基因检测：TMB-L,MSS，FBXW7 R505C；KNB-,BRCA-,ERBB2-,NTRK -，FGFR2-\",\"sample_type\":\"Surgical resection\",\"site\":\"Left adnexa\",\"tumor_size\":\"Unknown\",\"uncertainty_or_missing\":[\"Primary site unknown; recommended GI evaluation (gastroscopy negative)\"]}]},\"RADIOLOGY\":{\"next_imaging_plan\":{\"modality\":\"Unknown\",\"timing\":\"Unknown\"},\"studies\":[{\"anatomic_sites\":[\"Abdomen\",\"Pelvis\"],\"date\":\"Unknown\",\"findings\":[\"Postoperative PETCT: multiple abdominal and pelvic metastases\"],\"impression\":\"Multiple abdominal and pelvic metastases on PETCT\",\"modality\":\"Other\",\"trend_vs_prior\":\"Unknown\"},{\"anatomic_sites\":[\"Brain (cerebral sulcus)\"],\"date\":\"2025-01-20\",\"findings\":[\"Lesion in cerebral sulcus consistent with metastasis\"],\"impression\":\"Metastasis in cerebral sulcus\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Unknown\"},{\"anatomic_sites\":[\"Chest\",\"Abdomen\",\"Pelvis\"],\"date\":\"2025-01-28\",\"findings\":[\"Peritoneal thickening, abdominal and pelvic ascites; small pleural and peritoneal effusions; multiple enlarged lymph nodes\"],\"impression\":\"Peritoneal disease with nodal metastases and effusions\",\"modality\":\"CT\",\"trend_vs_prior\":\"Unknown\"},{\"anatomic_sites\":[\"Lower abdomen\",\"Pelvis\"],\"date\":\"2025-02-10\",\"findings\":[\"Peritoneal thickening, omental/mesenteric haziness with small nodules, retroperitoneal and pelvic lymphadenopathy, ascites; bilateral ureteral thickening\"],\"impression\":\"Widespread peritoneal and nodal disease with ascites\",\"modality\":\"CT\",\"trend_vs_prior\":\"Worse\"}]},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2024-12-20\",\"description\":\"Laparoscopy converted to laparotomy with uterus and bilateral adnexa resection and additional procedures\",\"event_type\":\"Surgery\",\"key_result\":\"Specimen: left adnexal Krukenberg tumor, mucinous adenocarcinoma with signet-ring differentiation\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2025-01-20\",\"description\":\"Head MRI\",\"event_type\":\"Imaging\",\"key_result\":\"Metastasis in cerebral sulcus\",\"regimen_or_test\":\"MRI\"},{\"date\":\"2025-01-28\",\"description\":\"Abdominal distension, left leg edema, pleural and peritoneal small effusions on ultrasound and CT\",\"event_type\":\"Other\",\"key_result\":\"Peritoneal thickening, ascites, multiple enlarged lymph nodes\",\"regimen_or_test\":\"Chest and abdominal CT/US\"},{\"date\":\"2025-02-10\",\"description\":\"Lower abdomen CT\",\"event_type\":\"Imaging\",\"key_result\":\"Peritoneal thickening, omental/mesenteric haziness with nodules, retroperitoneal and pelvic lymphadenopathy, ascites\",\"regimen_or_test\":\"CT\"},{\"date\":\"2025-02-10\",\"description\":\"Acute kidney injury with elevated creatinine and dizziness/hypertension\",\"event_type\":\"Lab\",\"key_result\":\"Cr 258.9 umol/L\",\"regimen_or_test\":\"Serum creatinine\"},{\"date\":\"2025-02-12\",\"description\":\"Ureteroscopy with bilateral stent placement\",\"event_type\":\"Other\",\"key_result\":\"Postop creatinine decreased to 170 umol/L\",\"regimen_or_test\":\"Ureteroscopy and stent\"},{\"date\":\"2025-02-14\",\"description\":\"Admission to Shanghai hospital for further treatment; episode of oliguria\",\"event_type\":\"Other\",\"key_result\":\"Urine output 100 ml\",\"regimen_or_test\":\"Inpatient care\"},{\"date\":\"2025-02-15\",\"description\":\"Transfer to nephrology and left percutaneous nephrostomy\",\"event_type\":\"Other\",\"key_result\":\"Condition stable after procedure\",\"regimen_or_test\":\"Left nephrostomy\"},{\"date\":\"2025-02-17\",\"description\":\"External genomic testing results reported\",\"event_type\":\"Other\",\"key_result\":\"TMB-L, MSS, FBXW7 R505C; KNB-, BRCA-, ERBB2-, NTRK-, FGFR2-\",\"regimen_or_test\":\"Genomic testing\"},{\"date\":\"2025-04-03\",\"description\":\"Document time of report\",\"event_type\":\"Other\",\"key_result\":\"Clinical summary recorded\",\"regimen_or_test\":\"Document\"}]}}", "final_output": "Final Assessment:\nMetastatic Krukenberg-type mucinous/signet carcinoma with brain and extensive peritoneal/ureteral involvement is in a palliative, systemically untreated state, with primary site, fitness for further therapy, and current renal function still uncertain [@HISTOLOGY_AND_IHC|2024-12-20; @IMAGING_TRENDS|2025-02-10; @IMAGING_STUDIES|2025-01-20].\n\nCore Treatment Strategy:\n- Conduct structured goals-of-care visit documenting ECOG, symptom burden, and preferences for further active versus comfort-focused care (currently unknown).  \n- Obtain updated labs including creatinine/eGFR and urine output assessment, with nephrology/urology review to define ongoing obstruction and treatment feasibility (unknown).  \n- Arrange contrast-enhanced CT/MRI abdomen–pelvis and repeat brain MRI to reassess peritoneal, nodal, ureteral, and CNS disease before systemic decisions [@IMAGING_TRENDS|2025-02-10; @IMAGING_STUDIES|2025-01-20].  \n- Confirm paraffin block availability and perform extended IHC only if primary-site clarification would realistically modify systemic regimen category (availability/status unknown).  \n\nChange Triggers:\n- If ECOG ≤2, renal function acceptable, and patient desires treatment, shift from evaluation-only to offering palliative systemic and CNS-directed therapy.  \n- If ECOG ≥3, progressive renal failure, or patient prefers comfort-focused care, pivot from active oncologic interventions to best supportive and hospice care.", "initial_ops": {"chair": "- Widely metastatic Krukenberg-type mucinous/signet tumor with brain and extensive peritoneal disease; prognosis poor, intent palliative systemic and local control.  \n- Urgent clarification of prior systemic therapy and platinum exposure (agents, cycles, dates, responses) is essential before choosing next-line regimen.  \n- Given brain metastasis, prioritize multidisciplinary neuro-oncology/rad-onc review for local treatment plus CNS-penetrant systemic strategy, if feasible.  \n- Renal function remains impaired (Cr ~110–170 µmol/L); nephrology input to optimize drainage, stents/nephrostomy, and chemotherapy dosing constraints.  \n- Confirm updated staging imaging, performance status, symptoms, and patient goals/preferences to balance active treatment versus early palliative-focused pathway.", "oncologist": "- Metastatic Krukenberg tumor with brain involvement; systemic therapy now palliative/relapse setting rather than curative.  \n\n- Renal function significantly impaired but improving; precise current creatinine, eGFR, and trend needed to choose/regimen-dose systemic therapy.  \n\n- No prior systemic therapy lines documented; must confirm any previous chemotherapy, dates, toxicities, and response.  \n\n- Biomarkers: HER2-, MSS, low TMB, HRD/BRCA wildtype—targeted/maintenance options limited; PD-L1, CA125, AFP levels unknown/need update.  \n\n- Need up-to-date brain and systemic imaging, performance status, and current medications to judge fitness for combination vs less intensive therapy.", "radiologist": "- Progressive diffuse peritoneal carcinomatosis with omental/mesenteric nodularity and increasing ascites, indicating worsening intra-abdominal disease burden [@IMAGING_STUDIES|2025-02-10].  \n\n- Retroperitoneal and pelvic lymphadenopathy consistent with nodal metastases; appears increased compared with earlier CT description [@IMAGING_STUDIES|2025-02-10].  \n\n- Bilateral ureteral thickening concerning for potential evolving ureteral obstruction; renal collecting system status unknown/needs update [@IMAGING_STUDIES|2025-02-10].  \n\n- Small pleural and peritoneal effusions persist, suggesting ongoing serosal involvement; no large pleural masses described [@IMAGING_STUDIES|2025-01-28].  \n\n- Solitary or limited cerebral sulcal metastasis on brain MRI; no trend or hemorrhage information available/needs update [@IMAGING_STUDIES|2025-01-20].", "pathologist": "- Morphology favors metastatic Krukenberg tumor with mixed mucinous and signet-ring cell features; primary gastrointestinal origin still unconfirmed.  \n\n- Extensive involvement of uterine wall, ureter, diaphragm, and lymph nodes indicates widely metastatic disease burden [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- ER/PR negative; no HER2 (ERBB2) amplification, MSS, low TMB, HRD/BRCA wildtype limit certain targeted biomarker options [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- Somatic FBXW7 R505C mutation present; clinical significance here uncertain and should be correlated with GI versus ovarian primary [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- Missing/needs update: detailed primary-site workup reports (upper/lower endoscopy, breast imaging), CA125/AFP, PD-L1 CPS, full panel IHC profile.", "nuclear": "- Prior PET/CT showed multiple abdominal and pelvic metastases, consistent with disseminated peritoneal and nodal involvement (advanced stage pattern). [@IMAGING_CONTEXT|Unknown]  \n\n- Subsequent imaging demonstrates cerebral sulcal metastasis, indicating distant metastatic spread beyond peritoneal cavity. [@IMAGING_CONTEXT|2025-01-20]  \n\n- Progressive widespread peritoneal and nodal disease with ascites suggests high whole-abdomen tumor burden. [@IMAGING_CONTEXT|2025-01-28] [@IMAGING_CONTEXT|2025-02-10]  \n\n- No current PET/CT report available for this visit; updated whole-body PET/CT report is needed to reassess metabolic disease extent.  \n\n- PET would meaningfully refine staging/recurrence suspicion by clarifying active peritoneal, nodal, and distant (e.g., brain) metabolic disease distribution."}, "merged_summary": "Key Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with extensive peritoneal, nodal, and brain disease; prognosis poor, management palliative.\n- Pattern favors metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted/maintenance options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal progression, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), constraining systemic therapy dosing/choice.\n\nControversies:\n- Primary site (GI vs other) remains unproven; extended IHC may refine origin and influence systemic strategy.\n- Benefit of PET/CT in a clearly palliative, widely metastatic setting versus CT/MRI alone, and whether results would change management.\n- Optimal CNS approach (local vs combined with CNS-penetrant systemic therapy) pending updated imaging and specialist review.\n\nMissing Info:\n- Full prior systemic therapy details (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI and systemic imaging (including contrast CT/MRI for ureteral/obstruction assessment), ECOG PS, symptoms, and medications.\n- Primary-site workup: availability of tissue/blocks for extended IHC (CDX2, SATB2, CK7/20, PAX8, MUC), plus endoscopy/breast imaging, CA125, AFP, PD-L1 CPS.\n- Decision on and, if chosen, results of any whole-body PET/CT with full head coverage and MRI coregistration.\n\nWorking Plan:\n- Verify prior systemic therapy history and update labs (especially renal) and performance status to frame feasible palliative systemic options.\n- Confirm tissue/block availability and request extended IHC to better define primary site if results would influence systemic decision-making.\n- Arrange neuro-oncology/radiation MDT review for brain metastasis and consider CNS-penetrant systemic strategy where appropriate.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing limits; repeat contrast-enhanced CT/MRI to reassess obstruction.\n- Decide if PET/CT would meaningfully alter management before ordering; if done, ensure full head coverage and fusion with latest brain MRI.\n- Proceed with structured goals-of-care and palliative planning discussions aligned with prognosis and patient preferences.", "final_round_ops": {"Round 1": {"chair": "- Maintain palliative intent, contingent on updated ECOG, symptom burden, and patient goals (active treatment vs comfort-focused pathway; details unknown).  \n- Clarify prior systemic therapy and platinum exposure (agents, cycles, dates, responses, toxicities all unknown) before proposing further systemic options.  \n- Obtain updated renal function (current creatinine, eGFR, obstruction status, urology/nephrology assessment unknown) to define feasibility and dosing of systemic therapy.  \n- Coordinate extended IHC on available tissue (block availability and panel completion unknown) to better assign primary site and inform regimen choice.  \n- Re-stage with updated brain MRI and contrast CT/MRI abdomen–pelvis (±PET/CT only if clearly management-changing), then review in MDT.", "oncologist": "- Confirm prior systemic therapies, toxicities, and responses; without this, selecting appropriate palliative systemic options remains unsafe (unknown/needs update).  \n\n- Obtain current creatinine, eGFR, and updated cross‑sectional imaging of abdomen/pelvis to reassess obstruction and systemic dosing feasibility (unknown/needs update).  \n\n- Arrange updated brain MRI and neuro-oncology/radiation review to determine local versus combined CNS-directed and systemic palliative strategy (unknown/needs update).  \n\n- Proceed with extended IHC on available tissue, if blocks accessible, to better define primary site and guide regimen category (unknown/needs update).  \n\n- Clarify ECOG PS, symptom burden, goals of care, and whether PET/CT would change management before ordering further staging (unknown/needs update).", "radiologist": "- Obtain updated contrast-enhanced CT or MRI abdomen/pelvis to reassess peritoneal burden, nodal disease, ascites, and ureteral obstruction risk [@IMAGING_STUDIES|2025-02-10].  \n\n- Repeat brain MRI to evaluate current cerebral sulcal metastasis extent, edema, and hemorrhage status for CNS-directed planning [@IMAGING_STUDIES|2025-01-20].  \n\n- If PET/CT is pursued, ensure whole-body coverage including brain and co-register with latest MRI to assess CNS/metabolic burden [@IMAGING_STUDIES|Unknown].  \n\n- Correlate new imaging with updated renal function and urology/nephrology input to guide palliative decompression and imaging contrast use (labs unknown).  \n\n- Reassess overall disease trend on new imaging to inform prognosis discussions and scope of palliative local versus systemic interventions [@IMAGING_TRENDS|2025-02-10].", "pathologist": "- Confirm if existing paraffin blocks/slides are available and suitable for extended IHC to refine GI vs ovarian primary (unknown/needs update).  \n\n- If tissue available, perform targeted IHC panel (CK7/CK20, CDX2, SATB2, PAX8, MUCs) to better assign primary (unknown/needs update).  \n\n- Maintain current diagnosis of metastatic Krukenberg-type mucinous/signet carcinoma with extensive peritoneal, nodal, uterine, ureteral, and diaphragmatic involvement [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- Note biomarker profile: ER/PR negative, HER2-/ERBB2-, MSS, low TMB, BRCA/HRD wildtype, FBXW7 R505C mutation [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- No pathology role regarding PET/CT or CNS imaging; defer imaging decisions to radiology/nuclear medicine and oncology teams.", "nuclear": "- No recent PET/CT is available; its value should be weighed against limited likelihood of management change in this palliative setting.  \n\n- If pursued, a single whole-body PET/CT with full head coverage could better map active extra-abdominal and CNS disease; current extent otherwise unknown/needs update.  \n\n- PET/CT may help distinguish metabolically active peritoneal/nodal deposits from treated or non-malignant changes, but impact on systemic choices remains uncertain.  \n\n- PET/CT would not define the primary site; that depends on extended IHC and GI/breast workup (status unknown/needs update).  \n\n- Coordination with updated brain MRI and contrast-enhanced CT/MRI abdomen–pelvis is essential for accurate fusion and obstruction/CNS risk assessment; timing unknown."}, "Round 2": {"chair": "- Maintain palliative intent and conduct goals-of-care discussion, aligning active treatment aggressiveness with prognosis and patient preferences (current symptoms/ECOG unknown).  \n- Clarify prior systemic therapies and platinum exposure (all details unknown) and update labs, especially renal function and eGFR (current values unknown).  \n- Confirm block availability and perform extended IHC to better define primary site, but only if results will alter systemic strategy (status unknown).  \n- Obtain updated brain MRI and contrast-enhanced CT/MRI abdomen–pelvis to reassess CNS disease and obstruction, then review with neuro-oncology/urology.  \n- Consider PET/CT only if MDT agrees results could meaningfully change palliative systemic or local interventions; otherwise rely on targeted CT/MRI restaging.", "oncologist": "- Clarify prior systemic therapies, responses, and toxicities; without this, it is unsafe to select further palliative regimens (unknown/needs update).  \n\n- Obtain current creatinine, eGFR, and contrast-enhanced abdominal/pelvic imaging to reassess obstruction and systemic dosing constraints (unknown/needs update).  \n\n- Confirm tissue/block availability and perform extended IHC if feasible, only if primary-site clarification would alter systemic strategy (unknown/needs update).  \n\n- Arrange updated brain MRI and neuro-oncology/radiation review to define local versus combined CNS‑directed and systemic approach (unknown/needs update).  \n\n- Document ECOG PS, symptom burden, goals of care, and decide if PET/CT would change management before ordering further staging (unknown/needs update).", "radiologist": "- Repeat contrast-enhanced CT or MRI abdomen/pelvis to reassess peritoneal disease, nodal burden, ascites, and ureteral obstruction risk [@IMAGING_STUDIES|2025-02-10].  \n\n- Obtain updated brain MRI to define current extent of cerebral sulcal metastasis, edema, and hemorrhage risk [@IMAGING_STUDIES|2025-01-20].  \n\n- Consider PET/CT only if results would alter management; if done, include whole head and coregister with MRI [@IMAGING_STUDIES|Unknown].  \n\n- Integrate new imaging with current renal function and urology/nephrology input to guide contrast use and local decompressive interventions (labs unknown).  \n\n- Use updated imaging trends to support prognosis communication and selection of symptom-directed palliative procedures versus further systemic therapy [@IMAGING_TRENDS|2025-02-10].", "pathologist": "- Maintain diagnosis: metastatic Krukenberg-type mucinous carcinoma with signet-ring features involving adnexa, uterus, ureter, diaphragm, nodes [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- Biomarkers: ER/PR-, HER2-/ERBB2-, MSS, TMB-L, BRCA/HRD wildtype, FBXW7 R505C mutation [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- Primary site remains unassigned (GI vs other); morphology alone insufficient for definitive origin [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- Clarify availability of existing blocks/slides for extended IHC (CK7/20, CDX2, SATB2, PAX8, MUC panel) to refine origin (unknown/needs update).  \n\n- No pathology-specific input on PET/CT or CNS imaging; defer to radiology/nuclear and oncology for those decisions.", "nuclear": "- No recent PET/CT available; current metabolic disease extent and activity remain unknown/needs update.  \n\n- In this extensively metastatic, palliative setting, PET/CT should be ordered only if results are expected to change management.  \n\n- If performed, whole-body PET/CT with full head coverage and MRI fusion could better delineate active CNS and extra-abdominal disease.  \n\n- PET/CT may help differentiate active peritoneal/nodal disease from treated or non-malignant changes, but staging is already clearly metastatic.  \n\n- PET/CT will not clarify primary origin; this depends on extended IHC and other site-directed investigations (status unknown/needs update)."}}, "interaction_log": {"Round 1": {"Turn 1": {"chair": {"chair": null, "oncologist": "Before committing to any systemic regimen, we must first document exact prior chemotherapy exposure, current ECOG, and up-to-date renal function/eGFR, given recent obstructive AKI and nephrostomy/stents.", "radiologist": "Please propose an imaging plan (timing and modalities) to reassess brain metastasis and systemic disease, considering prior CT/MRI and potential PET/CT utility.", "pathologist": "Can you clarify, based on existing histology/IHC and genomics, how strongly a GI primary is supported and what additional stains/tests would most efficiently refine the primary-site diagnosis?", "nuclear": "From your perspective, would a whole-body PET/CT meaningfully change management in this patient with known widespread peritoneal and brain metastases, or should we prioritize conventional CT/MRI only?"}, "oncologist": {"chair": "Systemic regimen choice is currently unsafe to finalize because prior systemic therapies, detailed renal function, and ECOG status are all undocumented and critical for dosing/feasibility.", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": "Key staging images are over 7 weeks old; updated cross-sectional and brain imaging are needed to guide current palliative planning.", "oncologist": "Before further systemic decisions, updated CT/MRI (chest/abdomen/pelvis and brain) is critical to reassess obstruction, peritoneal burden, and CNS disease extent.", "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": "Pathology workup for primary site is incomplete; please confirm whether additional tissue or outside blocks are available for extended IHC to refine primary assignment.", "oncologist": "Primary remains unproven (GI vs other); extended IHC panel (CDX2, SATB2, CK7/20, PAX8, MUC markers) on available tissue would better define origin and may influence systemic choices.", "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": "No recent PET/CT is available; if prognosis and goals permit, a single whole-body PET/CT could clarify current metabolic burden versus CT alone, especially extra-abdominal disease and brain involvement correlation.", "radiologist": "If PET/CT is pursued, please ensure brain-included acquisition and tight coregistration with latest MRI to assess metabolic activity of sulcal lesions and any additional CNS foci.", "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": "Before ordering PET/CT, we should clarify how its results would practically alter systemic or CNS management in a patient already deemed palliative with extensive disease.", "radiologist": null, "pathologist": "Please confirm availability of existing tissue/blocks and feasibility of extended IHC now, as primary-site assignment may materially affect systemic strategy discussions.", "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": "Given prior CT evidence of bilateral ureteral thickening and worsening peritoneal disease, updated contrast-enhanced CT (or MRI) is important to reassess obstruction risk and guide palliative interventions.", "radiologist": null, "pathologist": null, "nuclear": "If PET/CT is obtained, please include full head coverage and ensure fusion with the most recent brain MRI for accurate CNS assessment."}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}, "Round 2": {"Turn 1": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}}, "agent_logs": {"chair": [{"role": "chair", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Widely metastatic Krukenberg-type mucinous/signet tumor with brain and extensive peritoneal disease; prognosis poor, intent palliative systemic and local control.  \n- Urgent clarification of prior systemic therapy and platinum exposure (agents, cycles, dates, responses) is essential before choosing next-line regimen.  \n- Given brain metastasis, prioritize multidisciplinary neuro-oncology/rad-onc review for local treatment plus CNS-penetrant systemic strategy, if feasible.  \n- Renal function remains impaired (Cr ~110–170 µmol/L); nephrology input to optimize drainage, stents/nephrostomy, and chemotherapy dosing constraints.  \n- Confirm updated staging imaging, performance status, symptoms, and patient goals/preferences to balance active treatment versus early palliative-focused pathway.", "timestamp": "2026-01-17T23:01:59.069182"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2025-04-03 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Before committing to any systemic regimen, we must first document exact prior chemotherapy exposure, current ECOG, and up-to-date renal function/eGFR, given recent obstructive AKI and nephrostomy/stents.\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"Please propose an imaging plan (timing and modalities) to reassess brain metastasis and systemic disease, considering prior CT/MRI and potential PET/CT utility.\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"Can you clarify, based on existing histology/IHC and genomics, how strongly a GI primary is supported and what additional stains/tests would most efficiently refine the primary-site diagnosis?\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"From your perspective, would a whole-body PET/CT meaningfully change management in this patient with known widespread peritoneal and brain metastases, or should we prioritize conventional CT/MRI only?\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T23:02:20.970698"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2025-04-03 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n[R1T1 DELTA]  palliative planning. | pathologist->oncologist(missing): Primary remains unproven (GI vs other); extended IHC panel (CDX2, SATB2, CK7/20, PAX8, MUC markers) on available tissue would better define origin and may influence systemic choices. | pathologist->chair(missing): Pathology workup for primary site is incomplete; please confirm whether additional tissue or outside blocks are available for extended IHC to refine primary assignment. | nuclear->oncologist(missing): No recent PET/CT is available; if prognosis and goals permit, a single whole-body PET/CT could clarify current metabolic burden versus CT alone, especially extra-abdominal disease and brain involvement correlation. | nuclear->radiologist(missing): If PET/CT is pursued, please ensure brain-included acquisition and tight coregistration with latest MRI to assess metabolic activity of sulcal lesions and any additional CNS foci.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"pathologist\",\"message\":\"Please confirm availability of existing tissue/blocks and feasibility of extended IHC now, as primary-site assignment may materially affect systemic strategy discussions.\",\"why\":\"missing\"},{\"target\":\"oncologist\",\"message\":\"Before ordering PET/CT, we should clarify how its results would practically alter systemic or CNS management in a patient already deemed palliative with extensive disease.\",\"why\":\"safety\"}]}", "timestamp": "2026-01-17T23:02:29.475120"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n[R1T1 DELTA]  palliative planning. | pathologist->oncologist(missing): Primary remains unproven (GI vs other); extended IHC panel (CDX2, SATB2, CK7/20, PAX8, MUC markers) on available tissue would better define origin and may influence systemic choices. | pathologist->chair(missing): Pathology workup for primary site is incomplete; please confirm whether additional tissue or outside blocks are available for extended IHC to refine primary assignment. | nuclear->oncologist(missing): No recent PET/CT is available; if prognosis and goals permit, a single whole-body PET/CT could clarify current metabolic burden versus CT alone, especially extra-abdominal disease and brain involvement correlation. | nuclear->radiologist(missing): If PET/CT is pursued, please ensure brain-included acquisition and tight coregistration with latest MRI to assess metabolic activity of sulcal lesions and any additional CNS foci.\n[R1T2 DELTA] chair->pathologist(missing): Please confirm availability of existing tissue/blocks and feasibility of extended IHC now, as primary-site assignment may materially affect systemic strategy discussions. | chair->oncologist(safety): Before ordering PET/CT, we should clarify how its results would practically alter systemic or CNS management in a patient already deemed palliative with extensive disease. | radiologist->nuclear(missing): If PET/CT is obtained, please include full head coverage and ensure fusion with the most recent brain MRI for accurate CNS assessment. | radiologist->oncologist(missing): Given prior CT evidence of bilateral ureteral thickening and worsening peritoneal disease, updated contrast-enhanced CT (or MRI) is important to reassess obstruction risk and guide palliative interventions.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Maintain palliative intent, contingent on updated ECOG, symptom burden, and patient goals (active treatment vs comfort-focused pathway; details unknown).  \n- Clarify prior systemic therapy and platinum exposure (agents, cycles, dates, responses, toxicities all unknown) before proposing further systemic options.  \n- Obtain updated renal function (current creatinine, eGFR, obstruction status, urology/nephrology assessment unknown) to define feasibility and dosing of systemic therapy.  \n- Coordinate extended IHC on available tissue (block availability and panel completion unknown) to better assign primary site and inform regimen choice.  \n- Re-stage with updated brain MRI and contrast CT/MRI abdomen–pelvis (±PET/CT only if clearly management-changing), then review in MDT.", "timestamp": "2026-01-17T23:02:37.197322"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2025-04-03 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with extensive peritoneal, nodal, and brain disease; prognosis poor, management palliative.\n- Pattern favors metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted/maintenance options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal progression, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), constraining systemic therapy dosing/choice.\n\nControversies:\n- Primary site (GI vs other) remains unproven; extended IHC may refine origin and influence systemic strategy.\n- Benefit of PET/CT in a clearly palliative, widely metastatic setting versus CT/MRI alone, and whether results would change management.\n- Optimal CNS approach (local vs combined with CNS-penetrant systemic therapy) pending updated imaging and specialist review.\n\nMissing Info:\n- Full prior systemic therapy details (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI and systemic imaging (including contrast CT/MRI for ureteral/obstruction assessment), ECOG PS, symptoms, and medications.\n- Primary-site workup: availability of tissue/blocks for extended IHC (CDX2, SATB2, CK7/20, PAX8, MUC), plus endoscopy/breast imaging, CA125, AFP, PD-L1 CPS.\n- Decision on and, if chosen, results of any whole-body PET/CT with full head coverage and MRI coregistration.\n\nWorking Plan:\n- Verify prior systemic therapy history and update labs (especially renal) and performance status to frame feasible palliative systemic options.\n- Confirm tissue/block availability and request extended IHC to better define primary site if results would influence systemic decision-making.\n- Arrange neuro-oncology/radiation MDT review for brain metastasis and consider CNS-penetrant systemic strategy where appropriate.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing limits; repeat contrast-enhanced CT/MRI to reassess obstruction.\n- Decide if PET/CT would meaningfully alter management before ordering; if done, ensure full head coverage and fusion with latest brain MRI.\n- Proceed with structured goals-of-care and palliative planning discussions aligned with prognosis and patient preferences.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:03:27.727909"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with extensive peritoneal, nodal, and brain disease; prognosis poor, management palliative.\n- Pattern favors metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted/maintenance options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal progression, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), constraining systemic therapy dosing/choice.\n\nControversies:\n- Primary site (GI vs other) remains unproven; extended IHC may refine origin and influence systemic strategy.\n- Benefit of PET/CT in a clearly palliative, widely metastatic setting versus CT/MRI alone, and whether results would change management.\n- Optimal CNS approach (local vs combined with CNS-penetrant systemic therapy) pending updated imaging and specialist review.\n\nMissing Info:\n- Full prior systemic therapy details (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI and systemic imaging (including contrast CT/MRI for ureteral/obstruction assessment), ECOG PS, symptoms, and medications.\n- Primary-site workup: availability of tissue/blocks for extended IHC (CDX2, SATB2, CK7/20, PAX8, MUC), plus endoscopy/breast imaging, CA125, AFP, PD-L1 CPS.\n- Decision on and, if chosen, results of any whole-body PET/CT with full head coverage and MRI coregistration.\n\nWorking Plan:\n- Verify prior systemic therapy history and update labs (especially renal) and performance status to frame feasible palliative systemic options.\n- Confirm tissue/block availability and request extended IHC to better define primary site if results would influence systemic decision-making.\n- Arrange neuro-oncology/radiation MDT review for brain metastasis and consider CNS-penetrant systemic strategy where appropriate.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing limits; repeat contrast-enhanced CT/MRI to reassess obstruction.\n- Decide if PET/CT would meaningfully alter management before ordering; if done, ensure full head coverage and fusion with latest brain MRI.\n- Proceed with structured goals-of-care and palliative planning discussions aligned with prognosis and patient preferences.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Maintain palliative intent and conduct goals-of-care discussion, aligning active treatment aggressiveness with prognosis and patient preferences (current symptoms/ECOG unknown).  \n- Clarify prior systemic therapies and platinum exposure (all details unknown) and update labs, especially renal function and eGFR (current values unknown).  \n- Confirm block availability and perform extended IHC to better define primary site, but only if results will alter systemic strategy (status unknown).  \n- Obtain updated brain MRI and contrast-enhanced CT/MRI abdomen–pelvis to reassess CNS disease and obstruction, then review with neuro-oncology/urology.  \n- Consider PET/CT only if MDT agrees results could meaningfully change palliative systemic or local interventions; otherwise rely on targeted CT/MRI restaging.", "timestamp": "2026-01-17T23:04:08.708839"}, {"role": "chair", "user_message": "\nAs the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2025-04-03 15:38:50.183000.\nBased on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.\n\nSTRICT RULES:\n- Any factual statement about past tests/treatments must include [@report_id|date] or say unknown.\n- If experts disagree, pick the safest plan and state the key uncertainty.\n\n# FINAL REFINED PLANS (All experts, last round)\n{\n  \"Round 1\": {\n    \"chair\": \"- Maintain palliative intent, contingent on updated ECOG, symptom burden, and patient goals (active treatment vs comfort-focused pathway; details unknown).  \\n- Clarify prior systemic therapy and platinum exposure (agents, cycles, dates, responses, toxicities all unknown) before proposing further systemic options.  \\n- Obtain updated renal function (current creatinine, eGFR, obstruction status, urology/nephrology assessment unknown) to define feasibility and dosing of systemic therapy.  \\n- Coordinate extended IHC on available tissue (block availability and panel completion unknown) to better assign primary site and inform regimen choice.  \\n- Re-stage with updated brain MRI and contrast CT/MRI abdomen–pelvis (±PET/CT only if clearly management-changing), then review in MDT.\",\n    \"oncologist\": \"- Confirm prior systemic therapies, toxicities, and responses; without this, selecting appropriate palliative systemic options remains unsafe (unknown/needs update).  \\n\\n- Obtain current creatinine, eGFR, and updated cross‑sectional imaging of abdomen/pelvis to reassess obstruction and systemic dosing feasibility (unknown/needs update).  \\n\\n- Arrange updated brain MRI and neuro-oncology/radiation review to determine local versus combined CNS-directed and systemic palliative strategy (unknown/needs update).  \\n\\n- Proceed with extended IHC on available tissue, if blocks accessible, to better define primary site and guide regimen category (unknown/needs update).  \\n\\n- Clarify ECOG PS, symptom burden, goals of care, and whether PET/CT would change management before ordering further staging (unknown/needs update).\",\n    \"radiologist\": \"- Obtain updated contrast-enhanced CT or MRI abdomen/pelvis to reassess peritoneal burden, nodal disease, ascites, and ureteral obstruction risk [@IMAGING_STUDIES|2025-02-10].  \\n\\n- Repeat brain MRI to evaluate current cerebral sulcal metastasis extent, edema, and hemorrhage status for CNS-directed planning [@IMAGING_STUDIES|2025-01-20].  \\n\\n- If PET/CT is pursued, ensure whole-body coverage including brain and co-register with latest MRI to assess CNS/metabolic burden [@IMAGING_STUDIES|Unknown].  \\n\\n- Correlate new imaging with updated renal function and urology/nephrology input to guide palliative decompression and imaging contrast use (labs unknown).  \\n\\n- Reassess overall disease trend on new imaging to inform prognosis discussions and scope of palliative local versus systemic interventions [@IMAGING_TRENDS|2025-02-10].\",\n    \"pathologist\": \"- Confirm if existing paraffin blocks/slides are available and suitable for extended IHC to refine GI vs ovarian primary (unknown/needs update).  \\n\\n- If tissue available, perform targeted IHC panel (CK7/CK20, CDX2, SATB2, PAX8, MUCs) to better assign primary (unknown/needs update).  \\n\\n- Maintain current diagnosis of metastatic Krukenberg-type mucinous/signet carcinoma with extensive peritoneal, nodal, uterine, ureteral, and diaphragmatic involvement [@HISTOLOGY_AND_IHC|2024-12-20].  \\n\\n- Note biomarker profile: ER/PR negative, HER2-/ERBB2-, MSS, low TMB, BRCA/HRD wildtype, FBXW7 R505C mutation [@HISTOLOGY_AND_IHC|2024-12-20].  \\n\\n- No pathology role regarding PET/CT or CNS imaging; defer imaging decisions to radiology/nuclear medicine and oncology teams.\",\n    \"nuclear\": \"- No recent PET/CT is available; its value should be weighed against limited likelihood of management change in this palliative setting.  \\n\\n- If pursued, a single whole-body PET/CT with full head coverage could better map active extra-abdominal and CNS disease; current extent otherwise unknown/needs update.  \\n\\n- PET/CT may help distinguish metabolically active peritoneal/nodal deposits from treated or non-malignant changes, but impact on systemic choices remains uncertain.  \\n\\n- PET/CT would not define the primary site; that depends on extended IHC and GI/breast workup (status unknown/needs update).  \\n\\n- Coordination with updated brain MRI and contrast-enhanced CT/MRI abdomen–pelvis is essential for accurate fusion and obstruction/CNS risk assessment; timing unknown.\"\n  },\n  \"Round 2\": {\n    \"chair\": \"- Maintain palliative intent and conduct goals-of-care discussion, aligning active treatment aggressiveness with prognosis and patient preferences (current symptoms/ECOG unknown).  \\n- Clarify prior systemic therapies and platinum exposure (all details unknown) and update labs, especially renal function and eGFR (current values unknown).  \\n- Confirm block availability and perform extended IHC to better define primary site, but only if results will alter systemic strategy (status unknown).  \\n- Obtain updated brain MRI and contrast-enhanced CT/MRI abdomen–pelvis to reassess CNS disease and obstruction, then review with neuro-oncology/urology.  \\n- Consider PET/CT only if MDT agrees results could meaningfully change palliative systemic or local interventions; otherwise rely on targeted CT/MRI restaging.\",\n    \"oncologist\": \"- Clarify prior systemic therapies, responses, and toxicities; without this, it is unsafe to select further palliative regimens (unknown/needs update).  \\n\\n- Obtain current creatinine, eGFR, and contrast-enhanced abdominal/pelvic imaging to reassess obstruction and systemic dosing constraints (unknown/needs update).  \\n\\n- Confirm tissue/block availability and perform extended IHC if feasible, only if primary-site clarification would alter systemic strategy (unknown/needs update).  \\n\\n- Arrange updated brain MRI and neuro-oncology/radiation review to define local versus combined CNS‑directed and systemic approach (unknown/needs update).  \\n\\n- Document ECOG PS, symptom burden, goals of care, and decide if PET/CT would change management before ordering further staging (unknown/needs update).\",\n    \"radiologist\": \"- Repeat contrast-enhanced CT or MRI abdomen/pelvis to reassess peritoneal disease, nodal burden, ascites, and ureteral obstruction risk [@IMAGING_STUDIES|2025-02-10].  \\n\\n- Obtain updated brain MRI to define current extent of cerebral sulcal metastasis, edema, and hemorrhage risk [@IMAGING_STUDIES|2025-01-20].  \\n\\n- Consider PET/CT only if results would alter management; if done, include whole head and coregister with MRI [@IMAGING_STUDIES|Unknown].  \\n\\n- Integrate new imaging with current renal function and urology/nephrology input to guide contrast use and local decompressive interventions (labs unknown).  \\n\\n- Use updated imaging trends to support prognosis communication and selection of symptom-directed palliative procedures versus further systemic therapy [@IMAGING_TRENDS|2025-02-10].\",\n    \"pathologist\": \"- Maintain diagnosis: metastatic Krukenberg-type mucinous carcinoma with signet-ring features involving adnexa, uterus, ureter, diaphragm, nodes [@HISTOLOGY_AND_IHC|2024-12-20].  \\n\\n- Biomarkers: ER/PR-, HER2-/ERBB2-, MSS, TMB-L, BRCA/HRD wildtype, FBXW7 R505C mutation [@HISTOLOGY_AND_IHC|2024-12-20].  \\n\\n- Primary site remains unassigned (GI vs other); morphology alone insufficient for definitive origin [@HISTOLOGY_AND_IHC|2024-12-20].  \\n\\n- Clarify availability of existing blocks/slides for extended IHC (CK7/20, CDX2, SATB2, PAX8, MUC panel) to refine origin (unknown/needs update).  \\n\\n- No pathology-specific input on PET/CT or CNS imaging; defer to radiology/nuclear and oncology for those decisions.\",\n    \"nuclear\": \"- No recent PET/CT available; current metabolic disease extent and activity remain unknown/needs update.  \\n\\n- In this extensively metastatic, palliative setting, PET/CT should be ordered only if results are expected to change management.  \\n\\n- If performed, whole-body PET/CT with full head coverage and MRI fusion could better delineate active CNS and extra-abdominal disease.  \\n\\n- PET/CT may help differentiate active peritoneal/nodal disease from treated or non-malignant changes, but staging is already clearly metastatic.  \\n\\n- PET/CT will not clarify primary origin; this depends on extended IHC and other site-directed investigations (status unknown/needs update).\"\n  }\n}\n\n# Response Format\nFinal Assessment:\n<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>\n\nCore Treatment Strategy:\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n\nChange Triggers:\n- < ≤20 words “if X, then adjust management from A to B” >\n- < ≤20 words “if X, then adjust management from A to B” >\n", "assistant_reply": "Final Assessment:\nMetastatic Krukenberg-type mucinous/signet carcinoma with brain and extensive peritoneal/ureteral involvement is in a palliative, systemically untreated state, with primary site, fitness for further therapy, and current renal function still uncertain [@HISTOLOGY_AND_IHC|2024-12-20; @IMAGING_TRENDS|2025-02-10; @IMAGING_STUDIES|2025-01-20].\n\nCore Treatment Strategy:\n- Conduct structured goals-of-care visit documenting ECOG, symptom burden, and preferences for further active versus comfort-focused care (currently unknown).  \n- Obtain updated labs including creatinine/eGFR and urine output assessment, with nephrology/urology review to define ongoing obstruction and treatment feasibility (unknown).  \n- Arrange contrast-enhanced CT/MRI abdomen–pelvis and repeat brain MRI to reassess peritoneal, nodal, ureteral, and CNS disease before systemic decisions [@IMAGING_TRENDS|2025-02-10; @IMAGING_STUDIES|2025-01-20].  \n- Confirm paraffin block availability and perform extended IHC only if primary-site clarification would realistically modify systemic regimen category (availability/status unknown).  \n\nChange Triggers:\n- If ECOG ≤2, renal function acceptable, and patient desires treatment, shift from evaluation-only to offering palliative systemic and CNS-directed therapy.  \n- If ECOG ≥3, progressive renal failure, or patient prefers comfort-focused care, pivot from active oncologic interventions to best supportive and hospice care.", "timestamp": "2026-01-17T23:04:34.816633"}], "oncologist": [{"role": "oncologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Metastatic Krukenberg tumor with brain involvement; systemic therapy now palliative/relapse setting rather than curative.  \n\n- Renal function significantly impaired but improving; precise current creatinine, eGFR, and trend needed to choose/regimen-dose systemic therapy.  \n\n- No prior systemic therapy lines documented; must confirm any previous chemotherapy, dates, toxicities, and response.  \n\n- Biomarkers: HER2-, MSS, low TMB, HRD/BRCA wildtype—targeted/maintenance options limited; PD-L1, CA125, AFP levels unknown/need update.  \n\n- Need up-to-date brain and systemic imaging, performance status, and current medications to judge fitness for combination vs less intensive therapy.", "timestamp": "2026-01-17T23:02:01.688790"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2025-04-03 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Systemic regimen choice is currently unsafe to finalize because prior systemic therapies, detailed renal function, and ECOG status are all undocumented and critical for dosing/feasibility.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T23:02:22.439182"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2025-04-03 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n[R1T1 DELTA]  palliative planning. | pathologist->oncologist(missing): Primary remains unproven (GI vs other); extended IHC panel (CDX2, SATB2, CK7/20, PAX8, MUC markers) on available tissue would better define origin and may influence systemic choices. | pathologist->chair(missing): Pathology workup for primary site is incomplete; please confirm whether additional tissue or outside blocks are available for extended IHC to refine primary assignment. | nuclear->oncologist(missing): No recent PET/CT is available; if prognosis and goals permit, a single whole-body PET/CT could clarify current metabolic burden versus CT alone, especially extra-abdominal disease and brain involvement correlation. | nuclear->radiologist(missing): If PET/CT is pursued, please ensure brain-included acquisition and tight coregistration with latest MRI to assess metabolic activity of sulcal lesions and any additional CNS foci.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:02:30.566258"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n[R1T1 DELTA]  palliative planning. | pathologist->oncologist(missing): Primary remains unproven (GI vs other); extended IHC panel (CDX2, SATB2, CK7/20, PAX8, MUC markers) on available tissue would better define origin and may influence systemic choices. | pathologist->chair(missing): Pathology workup for primary site is incomplete; please confirm whether additional tissue or outside blocks are available for extended IHC to refine primary assignment. | nuclear->oncologist(missing): No recent PET/CT is available; if prognosis and goals permit, a single whole-body PET/CT could clarify current metabolic burden versus CT alone, especially extra-abdominal disease and brain involvement correlation. | nuclear->radiologist(missing): If PET/CT is pursued, please ensure brain-included acquisition and tight coregistration with latest MRI to assess metabolic activity of sulcal lesions and any additional CNS foci.\n[R1T2 DELTA] chair->pathologist(missing): Please confirm availability of existing tissue/blocks and feasibility of extended IHC now, as primary-site assignment may materially affect systemic strategy discussions. | chair->oncologist(safety): Before ordering PET/CT, we should clarify how its results would practically alter systemic or CNS management in a patient already deemed palliative with extensive disease. | radiologist->nuclear(missing): If PET/CT is obtained, please include full head coverage and ensure fusion with the most recent brain MRI for accurate CNS assessment. | radiologist->oncologist(missing): Given prior CT evidence of bilateral ureteral thickening and worsening peritoneal disease, updated contrast-enhanced CT (or MRI) is important to reassess obstruction risk and guide palliative interventions.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Confirm prior systemic therapies, toxicities, and responses; without this, selecting appropriate palliative systemic options remains unsafe (unknown/needs update).  \n\n- Obtain current creatinine, eGFR, and updated cross‑sectional imaging of abdomen/pelvis to reassess obstruction and systemic dosing feasibility (unknown/needs update).  \n\n- Arrange updated brain MRI and neuro-oncology/radiation review to determine local versus combined CNS-directed and systemic palliative strategy (unknown/needs update).  \n\n- Proceed with extended IHC on available tissue, if blocks accessible, to better define primary site and guide regimen category (unknown/needs update).  \n\n- Clarify ECOG PS, symptom burden, goals of care, and whether PET/CT would change management before ordering further staging (unknown/needs update).", "timestamp": "2026-01-17T23:03:06.811076"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2025-04-03 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with extensive peritoneal, nodal, and brain disease; prognosis poor, management palliative.\n- Pattern favors metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted/maintenance options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal progression, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), constraining systemic therapy dosing/choice.\n\nControversies:\n- Primary site (GI vs other) remains unproven; extended IHC may refine origin and influence systemic strategy.\n- Benefit of PET/CT in a clearly palliative, widely metastatic setting versus CT/MRI alone, and whether results would change management.\n- Optimal CNS approach (local vs combined with CNS-penetrant systemic therapy) pending updated imaging and specialist review.\n\nMissing Info:\n- Full prior systemic therapy details (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI and systemic imaging (including contrast CT/MRI for ureteral/obstruction assessment), ECOG PS, symptoms, and medications.\n- Primary-site workup: availability of tissue/blocks for extended IHC (CDX2, SATB2, CK7/20, PAX8, MUC), plus endoscopy/breast imaging, CA125, AFP, PD-L1 CPS.\n- Decision on and, if chosen, results of any whole-body PET/CT with full head coverage and MRI coregistration.\n\nWorking Plan:\n- Verify prior systemic therapy history and update labs (especially renal) and performance status to frame feasible palliative systemic options.\n- Confirm tissue/block availability and request extended IHC to better define primary site if results would influence systemic decision-making.\n- Arrange neuro-oncology/radiation MDT review for brain metastasis and consider CNS-penetrant systemic strategy where appropriate.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing limits; repeat contrast-enhanced CT/MRI to reassess obstruction.\n- Decide if PET/CT would meaningfully alter management before ordering; if done, ensure full head coverage and fusion with latest brain MRI.\n- Proceed with structured goals-of-care and palliative planning discussions aligned with prognosis and patient preferences.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:03:30.346436"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with extensive peritoneal, nodal, and brain disease; prognosis poor, management palliative.\n- Pattern favors metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted/maintenance options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal progression, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), constraining systemic therapy dosing/choice.\n\nControversies:\n- Primary site (GI vs other) remains unproven; extended IHC may refine origin and influence systemic strategy.\n- Benefit of PET/CT in a clearly palliative, widely metastatic setting versus CT/MRI alone, and whether results would change management.\n- Optimal CNS approach (local vs combined with CNS-penetrant systemic therapy) pending updated imaging and specialist review.\n\nMissing Info:\n- Full prior systemic therapy details (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI and systemic imaging (including contrast CT/MRI for ureteral/obstruction assessment), ECOG PS, symptoms, and medications.\n- Primary-site workup: availability of tissue/blocks for extended IHC (CDX2, SATB2, CK7/20, PAX8, MUC), plus endoscopy/breast imaging, CA125, AFP, PD-L1 CPS.\n- Decision on and, if chosen, results of any whole-body PET/CT with full head coverage and MRI coregistration.\n\nWorking Plan:\n- Verify prior systemic therapy history and update labs (especially renal) and performance status to frame feasible palliative systemic options.\n- Confirm tissue/block availability and request extended IHC to better define primary site if results would influence systemic decision-making.\n- Arrange neuro-oncology/radiation MDT review for brain metastasis and consider CNS-penetrant systemic strategy where appropriate.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing limits; repeat contrast-enhanced CT/MRI to reassess obstruction.\n- Decide if PET/CT would meaningfully alter management before ordering; if done, ensure full head coverage and fusion with latest brain MRI.\n- Proceed with structured goals-of-care and palliative planning discussions aligned with prognosis and patient preferences.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Clarify prior systemic therapies, responses, and toxicities; without this, it is unsafe to select further palliative regimens (unknown/needs update).  \n\n- Obtain current creatinine, eGFR, and contrast-enhanced abdominal/pelvic imaging to reassess obstruction and systemic dosing constraints (unknown/needs update).  \n\n- Confirm tissue/block availability and perform extended IHC if feasible, only if primary-site clarification would alter systemic strategy (unknown/needs update).  \n\n- Arrange updated brain MRI and neuro-oncology/radiation review to define local versus combined CNS‑directed and systemic approach (unknown/needs update).  \n\n- Document ECOG PS, symptom burden, goals of care, and decide if PET/CT would change management before ordering further staging (unknown/needs update).", "timestamp": "2026-01-17T23:04:11.187286"}], "radiologist": [{"role": "radiologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Progressive diffuse peritoneal carcinomatosis with omental/mesenteric nodularity and increasing ascites, indicating worsening intra-abdominal disease burden [@IMAGING_STUDIES|2025-02-10].  \n\n- Retroperitoneal and pelvic lymphadenopathy consistent with nodal metastases; appears increased compared with earlier CT description [@IMAGING_STUDIES|2025-02-10].  \n\n- Bilateral ureteral thickening concerning for potential evolving ureteral obstruction; renal collecting system status unknown/needs update [@IMAGING_STUDIES|2025-02-10].  \n\n- Small pleural and peritoneal effusions persist, suggesting ongoing serosal involvement; no large pleural masses described [@IMAGING_STUDIES|2025-01-28].  \n\n- Solitary or limited cerebral sulcal metastasis on brain MRI; no trend or hemorrhage information available/needs update [@IMAGING_STUDIES|2025-01-20].", "timestamp": "2026-01-17T23:02:04.192306"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2025-04-03 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Before further systemic decisions, updated CT/MRI (chest/abdomen/pelvis and brain) is critical to reassess obstruction, peritoneal burden, and CNS disease extent.\",\"why\":\"missing\"},{\"target\":\"chair\",\"message\":\"Key staging images are over 7 weeks old; updated cross-sectional and brain imaging are needed to guide current palliative planning.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T23:02:24.023372"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2025-04-03 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n[R1T1 DELTA]  palliative planning. | pathologist->oncologist(missing): Primary remains unproven (GI vs other); extended IHC panel (CDX2, SATB2, CK7/20, PAX8, MUC markers) on available tissue would better define origin and may influence systemic choices. | pathologist->chair(missing): Pathology workup for primary site is incomplete; please confirm whether additional tissue or outside blocks are available for extended IHC to refine primary assignment. | nuclear->oncologist(missing): No recent PET/CT is available; if prognosis and goals permit, a single whole-body PET/CT could clarify current metabolic burden versus CT alone, especially extra-abdominal disease and brain involvement correlation. | nuclear->radiologist(missing): If PET/CT is pursued, please ensure brain-included acquisition and tight coregistration with latest MRI to assess metabolic activity of sulcal lesions and any additional CNS foci.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"nuclear\",\"message\":\"If PET/CT is obtained, please include full head coverage and ensure fusion with the most recent brain MRI for accurate CNS assessment.\",\"why\":\"missing\"},{\"target\":\"oncologist\",\"message\":\"Given prior CT evidence of bilateral ureteral thickening and worsening peritoneal disease, updated contrast-enhanced CT (or MRI) is important to reassess obstruction risk and guide palliative interventions.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T23:02:32.382142"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n[R1T1 DELTA]  palliative planning. | pathologist->oncologist(missing): Primary remains unproven (GI vs other); extended IHC panel (CDX2, SATB2, CK7/20, PAX8, MUC markers) on available tissue would better define origin and may influence systemic choices. | pathologist->chair(missing): Pathology workup for primary site is incomplete; please confirm whether additional tissue or outside blocks are available for extended IHC to refine primary assignment. | nuclear->oncologist(missing): No recent PET/CT is available; if prognosis and goals permit, a single whole-body PET/CT could clarify current metabolic burden versus CT alone, especially extra-abdominal disease and brain involvement correlation. | nuclear->radiologist(missing): If PET/CT is pursued, please ensure brain-included acquisition and tight coregistration with latest MRI to assess metabolic activity of sulcal lesions and any additional CNS foci.\n[R1T2 DELTA] chair->pathologist(missing): Please confirm availability of existing tissue/blocks and feasibility of extended IHC now, as primary-site assignment may materially affect systemic strategy discussions. | chair->oncologist(safety): Before ordering PET/CT, we should clarify how its results would practically alter systemic or CNS management in a patient already deemed palliative with extensive disease. | radiologist->nuclear(missing): If PET/CT is obtained, please include full head coverage and ensure fusion with the most recent brain MRI for accurate CNS assessment. | radiologist->oncologist(missing): Given prior CT evidence of bilateral ureteral thickening and worsening peritoneal disease, updated contrast-enhanced CT (or MRI) is important to reassess obstruction risk and guide palliative interventions.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Obtain updated contrast-enhanced CT or MRI abdomen/pelvis to reassess peritoneal burden, nodal disease, ascites, and ureteral obstruction risk [@IMAGING_STUDIES|2025-02-10].  \n\n- Repeat brain MRI to evaluate current cerebral sulcal metastasis extent, edema, and hemorrhage status for CNS-directed planning [@IMAGING_STUDIES|2025-01-20].  \n\n- If PET/CT is pursued, ensure whole-body coverage including brain and co-register with latest MRI to assess CNS/metabolic burden [@IMAGING_STUDIES|Unknown].  \n\n- Correlate new imaging with updated renal function and urology/nephrology input to guide palliative decompression and imaging contrast use (labs unknown).  \n\n- Reassess overall disease trend on new imaging to inform prognosis discussions and scope of palliative local versus systemic interventions [@IMAGING_TRENDS|2025-02-10].", "timestamp": "2026-01-17T23:03:09.407993"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2025-04-03 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with extensive peritoneal, nodal, and brain disease; prognosis poor, management palliative.\n- Pattern favors metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted/maintenance options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal progression, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), constraining systemic therapy dosing/choice.\n\nControversies:\n- Primary site (GI vs other) remains unproven; extended IHC may refine origin and influence systemic strategy.\n- Benefit of PET/CT in a clearly palliative, widely metastatic setting versus CT/MRI alone, and whether results would change management.\n- Optimal CNS approach (local vs combined with CNS-penetrant systemic therapy) pending updated imaging and specialist review.\n\nMissing Info:\n- Full prior systemic therapy details (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI and systemic imaging (including contrast CT/MRI for ureteral/obstruction assessment), ECOG PS, symptoms, and medications.\n- Primary-site workup: availability of tissue/blocks for extended IHC (CDX2, SATB2, CK7/20, PAX8, MUC), plus endoscopy/breast imaging, CA125, AFP, PD-L1 CPS.\n- Decision on and, if chosen, results of any whole-body PET/CT with full head coverage and MRI coregistration.\n\nWorking Plan:\n- Verify prior systemic therapy history and update labs (especially renal) and performance status to frame feasible palliative systemic options.\n- Confirm tissue/block availability and request extended IHC to better define primary site if results would influence systemic decision-making.\n- Arrange neuro-oncology/radiation MDT review for brain metastasis and consider CNS-penetrant systemic strategy where appropriate.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing limits; repeat contrast-enhanced CT/MRI to reassess obstruction.\n- Decide if PET/CT would meaningfully alter management before ordering; if done, ensure full head coverage and fusion with latest brain MRI.\n- Proceed with structured goals-of-care and palliative planning discussions aligned with prognosis and patient preferences.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:03:32.992884"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with extensive peritoneal, nodal, and brain disease; prognosis poor, management palliative.\n- Pattern favors metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted/maintenance options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal progression, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), constraining systemic therapy dosing/choice.\n\nControversies:\n- Primary site (GI vs other) remains unproven; extended IHC may refine origin and influence systemic strategy.\n- Benefit of PET/CT in a clearly palliative, widely metastatic setting versus CT/MRI alone, and whether results would change management.\n- Optimal CNS approach (local vs combined with CNS-penetrant systemic therapy) pending updated imaging and specialist review.\n\nMissing Info:\n- Full prior systemic therapy details (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI and systemic imaging (including contrast CT/MRI for ureteral/obstruction assessment), ECOG PS, symptoms, and medications.\n- Primary-site workup: availability of tissue/blocks for extended IHC (CDX2, SATB2, CK7/20, PAX8, MUC), plus endoscopy/breast imaging, CA125, AFP, PD-L1 CPS.\n- Decision on and, if chosen, results of any whole-body PET/CT with full head coverage and MRI coregistration.\n\nWorking Plan:\n- Verify prior systemic therapy history and update labs (especially renal) and performance status to frame feasible palliative systemic options.\n- Confirm tissue/block availability and request extended IHC to better define primary site if results would influence systemic decision-making.\n- Arrange neuro-oncology/radiation MDT review for brain metastasis and consider CNS-penetrant systemic strategy where appropriate.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing limits; repeat contrast-enhanced CT/MRI to reassess obstruction.\n- Decide if PET/CT would meaningfully alter management before ordering; if done, ensure full head coverage and fusion with latest brain MRI.\n- Proceed with structured goals-of-care and palliative planning discussions aligned with prognosis and patient preferences.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Repeat contrast-enhanced CT or MRI abdomen/pelvis to reassess peritoneal disease, nodal burden, ascites, and ureteral obstruction risk [@IMAGING_STUDIES|2025-02-10].  \n\n- Obtain updated brain MRI to define current extent of cerebral sulcal metastasis, edema, and hemorrhage risk [@IMAGING_STUDIES|2025-01-20].  \n\n- Consider PET/CT only if results would alter management; if done, include whole head and coregister with MRI [@IMAGING_STUDIES|Unknown].  \n\n- Integrate new imaging with current renal function and urology/nephrology input to guide contrast use and local decompressive interventions (labs unknown).  \n\n- Use updated imaging trends to support prognosis communication and selection of symptom-directed palliative procedures versus further systemic therapy [@IMAGING_TRENDS|2025-02-10].", "timestamp": "2026-01-17T23:04:26.250060"}], "pathologist": [{"role": "pathologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Morphology favors metastatic Krukenberg tumor with mixed mucinous and signet-ring cell features; primary gastrointestinal origin still unconfirmed.  \n\n- Extensive involvement of uterine wall, ureter, diaphragm, and lymph nodes indicates widely metastatic disease burden [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- ER/PR negative; no HER2 (ERBB2) amplification, MSS, low TMB, HRD/BRCA wildtype limit certain targeted biomarker options [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- Somatic FBXW7 R505C mutation present; clinical significance here uncertain and should be correlated with GI versus ovarian primary [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- Missing/needs update: detailed primary-site workup reports (upper/lower endoscopy, breast imaging), CA125/AFP, PD-L1 CPS, full panel IHC profile.", "timestamp": "2026-01-17T23:02:06.932553"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2025-04-03 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Primary remains unproven (GI vs other); extended IHC panel (CDX2, SATB2, CK7/20, PAX8, MUC markers) on available tissue would better define origin and may influence systemic choices.\",\"why\":\"missing\"},{\"target\":\"chair\",\"message\":\"Pathology workup for primary site is incomplete; please confirm whether additional tissue or outside blocks are available for extended IHC to refine primary assignment.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T23:02:25.648211"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2025-04-03 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n[R1T1 DELTA]  palliative planning. | pathologist->oncologist(missing): Primary remains unproven (GI vs other); extended IHC panel (CDX2, SATB2, CK7/20, PAX8, MUC markers) on available tissue would better define origin and may influence systemic choices. | pathologist->chair(missing): Pathology workup for primary site is incomplete; please confirm whether additional tissue or outside blocks are available for extended IHC to refine primary assignment. | nuclear->oncologist(missing): No recent PET/CT is available; if prognosis and goals permit, a single whole-body PET/CT could clarify current metabolic burden versus CT alone, especially extra-abdominal disease and brain involvement correlation. | nuclear->radiologist(missing): If PET/CT is pursued, please ensure brain-included acquisition and tight coregistration with latest MRI to assess metabolic activity of sulcal lesions and any additional CNS foci.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:02:33.510911"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n[R1T1 DELTA]  palliative planning. | pathologist->oncologist(missing): Primary remains unproven (GI vs other); extended IHC panel (CDX2, SATB2, CK7/20, PAX8, MUC markers) on available tissue would better define origin and may influence systemic choices. | pathologist->chair(missing): Pathology workup for primary site is incomplete; please confirm whether additional tissue or outside blocks are available for extended IHC to refine primary assignment. | nuclear->oncologist(missing): No recent PET/CT is available; if prognosis and goals permit, a single whole-body PET/CT could clarify current metabolic burden versus CT alone, especially extra-abdominal disease and brain involvement correlation. | nuclear->radiologist(missing): If PET/CT is pursued, please ensure brain-included acquisition and tight coregistration with latest MRI to assess metabolic activity of sulcal lesions and any additional CNS foci.\n[R1T2 DELTA] chair->pathologist(missing): Please confirm availability of existing tissue/blocks and feasibility of extended IHC now, as primary-site assignment may materially affect systemic strategy discussions. | chair->oncologist(safety): Before ordering PET/CT, we should clarify how its results would practically alter systemic or CNS management in a patient already deemed palliative with extensive disease. | radiologist->nuclear(missing): If PET/CT is obtained, please include full head coverage and ensure fusion with the most recent brain MRI for accurate CNS assessment. | radiologist->oncologist(missing): Given prior CT evidence of bilateral ureteral thickening and worsening peritoneal disease, updated contrast-enhanced CT (or MRI) is important to reassess obstruction risk and guide palliative interventions.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Confirm if existing paraffin blocks/slides are available and suitable for extended IHC to refine GI vs ovarian primary (unknown/needs update).  \n\n- If tissue available, perform targeted IHC panel (CK7/CK20, CDX2, SATB2, PAX8, MUCs) to better assign primary (unknown/needs update).  \n\n- Maintain current diagnosis of metastatic Krukenberg-type mucinous/signet carcinoma with extensive peritoneal, nodal, uterine, ureteral, and diaphragmatic involvement [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- Note biomarker profile: ER/PR negative, HER2-/ERBB2-, MSS, low TMB, BRCA/HRD wildtype, FBXW7 R505C mutation [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- No pathology role regarding PET/CT or CNS imaging; defer imaging decisions to radiology/nuclear medicine and oncology teams.", "timestamp": "2026-01-17T23:03:19.280209"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2025-04-03 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with extensive peritoneal, nodal, and brain disease; prognosis poor, management palliative.\n- Pattern favors metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted/maintenance options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal progression, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), constraining systemic therapy dosing/choice.\n\nControversies:\n- Primary site (GI vs other) remains unproven; extended IHC may refine origin and influence systemic strategy.\n- Benefit of PET/CT in a clearly palliative, widely metastatic setting versus CT/MRI alone, and whether results would change management.\n- Optimal CNS approach (local vs combined with CNS-penetrant systemic therapy) pending updated imaging and specialist review.\n\nMissing Info:\n- Full prior systemic therapy details (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI and systemic imaging (including contrast CT/MRI for ureteral/obstruction assessment), ECOG PS, symptoms, and medications.\n- Primary-site workup: availability of tissue/blocks for extended IHC (CDX2, SATB2, CK7/20, PAX8, MUC), plus endoscopy/breast imaging, CA125, AFP, PD-L1 CPS.\n- Decision on and, if chosen, results of any whole-body PET/CT with full head coverage and MRI coregistration.\n\nWorking Plan:\n- Verify prior systemic therapy history and update labs (especially renal) and performance status to frame feasible palliative systemic options.\n- Confirm tissue/block availability and request extended IHC to better define primary site if results would influence systemic decision-making.\n- Arrange neuro-oncology/radiation MDT review for brain metastasis and consider CNS-penetrant systemic strategy where appropriate.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing limits; repeat contrast-enhanced CT/MRI to reassess obstruction.\n- Decide if PET/CT would meaningfully alter management before ordering; if done, ensure full head coverage and fusion with latest brain MRI.\n- Proceed with structured goals-of-care and palliative planning discussions aligned with prognosis and patient preferences.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:03:34.107264"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with extensive peritoneal, nodal, and brain disease; prognosis poor, management palliative.\n- Pattern favors metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted/maintenance options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal progression, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), constraining systemic therapy dosing/choice.\n\nControversies:\n- Primary site (GI vs other) remains unproven; extended IHC may refine origin and influence systemic strategy.\n- Benefit of PET/CT in a clearly palliative, widely metastatic setting versus CT/MRI alone, and whether results would change management.\n- Optimal CNS approach (local vs combined with CNS-penetrant systemic therapy) pending updated imaging and specialist review.\n\nMissing Info:\n- Full prior systemic therapy details (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI and systemic imaging (including contrast CT/MRI for ureteral/obstruction assessment), ECOG PS, symptoms, and medications.\n- Primary-site workup: availability of tissue/blocks for extended IHC (CDX2, SATB2, CK7/20, PAX8, MUC), plus endoscopy/breast imaging, CA125, AFP, PD-L1 CPS.\n- Decision on and, if chosen, results of any whole-body PET/CT with full head coverage and MRI coregistration.\n\nWorking Plan:\n- Verify prior systemic therapy history and update labs (especially renal) and performance status to frame feasible palliative systemic options.\n- Confirm tissue/block availability and request extended IHC to better define primary site if results would influence systemic decision-making.\n- Arrange neuro-oncology/radiation MDT review for brain metastasis and consider CNS-penetrant systemic strategy where appropriate.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing limits; repeat contrast-enhanced CT/MRI to reassess obstruction.\n- Decide if PET/CT would meaningfully alter management before ordering; if done, ensure full head coverage and fusion with latest brain MRI.\n- Proceed with structured goals-of-care and palliative planning discussions aligned with prognosis and patient preferences.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Maintain diagnosis: metastatic Krukenberg-type mucinous carcinoma with signet-ring features involving adnexa, uterus, ureter, diaphragm, nodes [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- Biomarkers: ER/PR-, HER2-/ERBB2-, MSS, TMB-L, BRCA/HRD wildtype, FBXW7 R505C mutation [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- Primary site remains unassigned (GI vs other); morphology alone insufficient for definitive origin [@HISTOLOGY_AND_IHC|2024-12-20].  \n\n- Clarify availability of existing blocks/slides for extended IHC (CK7/20, CDX2, SATB2, PAX8, MUC panel) to refine origin (unknown/needs update).  \n\n- No pathology-specific input on PET/CT or CNS imaging; defer to radiology/nuclear and oncology for those decisions.", "timestamp": "2026-01-17T23:04:28.759482"}], "nuclear": [{"role": "nuclear", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Prior PET/CT showed multiple abdominal and pelvic metastases, consistent with disseminated peritoneal and nodal involvement (advanced stage pattern). [@IMAGING_CONTEXT|Unknown]  \n\n- Subsequent imaging demonstrates cerebral sulcal metastasis, indicating distant metastatic spread beyond peritoneal cavity. [@IMAGING_CONTEXT|2025-01-20]  \n\n- Progressive widespread peritoneal and nodal disease with ascites suggests high whole-abdomen tumor burden. [@IMAGING_CONTEXT|2025-01-28] [@IMAGING_CONTEXT|2025-02-10]  \n\n- No current PET/CT report available for this visit; updated whole-body PET/CT report is needed to reassess metabolic disease extent.  \n\n- PET would meaningfully refine staging/recurrence suspicion by clarifying active peritoneal, nodal, and distant (e.g., brain) metabolic disease distribution.", "timestamp": "2026-01-17T23:02:09.660225"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2025-04-03 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"No recent PET/CT is available; if prognosis and goals permit, a single whole-body PET/CT could clarify current metabolic burden versus CT alone, especially extra-abdominal disease and brain involvement correlation.\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"If PET/CT is pursued, please ensure brain-included acquisition and tight coregistration with latest MRI to assess metabolic activity of sulcal lesions and any additional CNS foci.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T23:02:27.684102"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2025-04-03 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n[R1T1 DELTA]  palliative planning. | pathologist->oncologist(missing): Primary remains unproven (GI vs other); extended IHC panel (CDX2, SATB2, CK7/20, PAX8, MUC markers) on available tissue would better define origin and may influence systemic choices. | pathologist->chair(missing): Pathology workup for primary site is incomplete; please confirm whether additional tissue or outside blocks are available for extended IHC to refine primary assignment. | nuclear->oncologist(missing): No recent PET/CT is available; if prognosis and goals permit, a single whole-body PET/CT could clarify current metabolic burden versus CT alone, especially extra-abdominal disease and brain involvement correlation. | nuclear->radiologist(missing): If PET/CT is pursued, please ensure brain-included acquisition and tight coregistration with latest MRI to assess metabolic activity of sulcal lesions and any additional CNS foci.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:02:34.792766"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n[R1T1 DELTA]  palliative planning. | pathologist->oncologist(missing): Primary remains unproven (GI vs other); extended IHC panel (CDX2, SATB2, CK7/20, PAX8, MUC markers) on available tissue would better define origin and may influence systemic choices. | pathologist->chair(missing): Pathology workup for primary site is incomplete; please confirm whether additional tissue or outside blocks are available for extended IHC to refine primary assignment. | nuclear->oncologist(missing): No recent PET/CT is available; if prognosis and goals permit, a single whole-body PET/CT could clarify current metabolic burden versus CT alone, especially extra-abdominal disease and brain involvement correlation. | nuclear->radiologist(missing): If PET/CT is pursued, please ensure brain-included acquisition and tight coregistration with latest MRI to assess metabolic activity of sulcal lesions and any additional CNS foci.\n[R1T2 DELTA] chair->pathologist(missing): Please confirm availability of existing tissue/blocks and feasibility of extended IHC now, as primary-site assignment may materially affect systemic strategy discussions. | chair->oncologist(safety): Before ordering PET/CT, we should clarify how its results would practically alter systemic or CNS management in a patient already deemed palliative with extensive disease. | radiologist->nuclear(missing): If PET/CT is obtained, please include full head coverage and ensure fusion with the most recent brain MRI for accurate CNS assessment. | radiologist->oncologist(missing): Given prior CT evidence of bilateral ureteral thickening and worsening peritoneal disease, updated contrast-enhanced CT (or MRI) is important to reassess obstruction risk and guide palliative interventions.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- No recent PET/CT is available; its value should be weighed against limited likelihood of management change in this palliative setting.  \n\n- If pursued, a single whole-body PET/CT with full head coverage could better map active extra-abdominal and CNS disease; current extent otherwise unknown/needs update.  \n\n- PET/CT may help distinguish metabolically active peritoneal/nodal deposits from treated or non-malignant changes, but impact on systemic choices remains uncertain.  \n\n- PET/CT would not define the primary site; that depends on extended IHC and GI/breast workup (status unknown/needs update).  \n\n- Coordination with updated brain MRI and contrast-enhanced CT/MRI abdomen–pelvis is essential for accurate fusion and obstruction/CNS risk assessment; timing unknown.", "timestamp": "2026-01-17T23:03:21.905067"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2025-04-03 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with extensive peritoneal, nodal, and brain disease; prognosis poor, management palliative.\n- Pattern favors metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted/maintenance options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal progression, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), constraining systemic therapy dosing/choice.\n\nControversies:\n- Primary site (GI vs other) remains unproven; extended IHC may refine origin and influence systemic strategy.\n- Benefit of PET/CT in a clearly palliative, widely metastatic setting versus CT/MRI alone, and whether results would change management.\n- Optimal CNS approach (local vs combined with CNS-penetrant systemic therapy) pending updated imaging and specialist review.\n\nMissing Info:\n- Full prior systemic therapy details (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI and systemic imaging (including contrast CT/MRI for ureteral/obstruction assessment), ECOG PS, symptoms, and medications.\n- Primary-site workup: availability of tissue/blocks for extended IHC (CDX2, SATB2, CK7/20, PAX8, MUC), plus endoscopy/breast imaging, CA125, AFP, PD-L1 CPS.\n- Decision on and, if chosen, results of any whole-body PET/CT with full head coverage and MRI coregistration.\n\nWorking Plan:\n- Verify prior systemic therapy history and update labs (especially renal) and performance status to frame feasible palliative systemic options.\n- Confirm tissue/block availability and request extended IHC to better define primary site if results would influence systemic decision-making.\n- Arrange neuro-oncology/radiation MDT review for brain metastasis and consider CNS-penetrant systemic strategy where appropriate.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing limits; repeat contrast-enhanced CT/MRI to reassess obstruction.\n- Decide if PET/CT would meaningfully alter management before ordering; if done, ensure full head coverage and fusion with latest brain MRI.\n- Proceed with structured goals-of-care and palliative planning discussions aligned with prognosis and patient preferences.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:03:36.602937"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with extensive peritoneal, nodal, and brain disease; prognosis poor, management palliative.\n- Pattern favors metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted/maintenance options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal progression, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), constraining systemic therapy dosing/choice.\n\nControversies:\n- Primary site (GI vs other) remains unproven; extended IHC may refine origin and influence systemic strategy.\n- Benefit of PET/CT in a clearly palliative, widely metastatic setting versus CT/MRI alone, and whether results would change management.\n- Optimal CNS approach (local vs combined with CNS-penetrant systemic therapy) pending updated imaging and specialist review.\n\nMissing Info:\n- Full prior systemic therapy details (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI and systemic imaging (including contrast CT/MRI for ureteral/obstruction assessment), ECOG PS, symptoms, and medications.\n- Primary-site workup: availability of tissue/blocks for extended IHC (CDX2, SATB2, CK7/20, PAX8, MUC), plus endoscopy/breast imaging, CA125, AFP, PD-L1 CPS.\n- Decision on and, if chosen, results of any whole-body PET/CT with full head coverage and MRI coregistration.\n\nWorking Plan:\n- Verify prior systemic therapy history and update labs (especially renal) and performance status to frame feasible palliative systemic options.\n- Confirm tissue/block availability and request extended IHC to better define primary site if results would influence systemic decision-making.\n- Arrange neuro-oncology/radiation MDT review for brain metastasis and consider CNS-penetrant systemic strategy where appropriate.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing limits; repeat contrast-enhanced CT/MRI to reassess obstruction.\n- Decide if PET/CT would meaningfully alter management before ordering; if done, ensure full head coverage and fusion with latest brain MRI.\n- Proceed with structured goals-of-care and palliative planning discussions aligned with prognosis and patient preferences.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- No recent PET/CT available; current metabolic disease extent and activity remain unknown/needs update.  \n\n- In this extensively metastatic, palliative setting, PET/CT should be ordered only if results are expected to change management.  \n\n- If performed, whole-body PET/CT with full head coverage and MRI fusion could better delineate active CNS and extra-abdominal disease.  \n\n- PET/CT may help differentiate active peritoneal/nodal disease from treated or non-malignant changes, but staging is already clearly metastatic.  \n\n- PET/CT will not clarify primary origin; this depends on extended IHC and other site-directed investigations (status unknown/needs update).", "timestamp": "2026-01-17T23:04:30.893970"}], "assistant": [{"role": "assistant", "user_message": "Summarize expert opinions concisely for MDT.\n{\"chair\":\"- Widely metastatic Krukenberg-type mucinous/signet tumor with brain and extensive peritoneal disease; prognosis poor, intent palliative systemic and local control.  \\n- Urgent clarification of prior systemic therapy and platinum exposure (agents, cycles, dates, responses) is essential before choosing next-line regimen.  \\n- Given brain metastasis, prioritize multidisciplinary neuro-oncology/rad-onc review for local treatment plus CNS-penetrant systemic strategy, if feasible.  \\n- Renal function remains impaired (Cr ~110–170 µmol/L); nephrology input to optimize drainage, stents/nephrostomy, and chemotherapy dosing constraints.  \\n- Confirm updated staging imaging, performance status, symptoms, and patient goals/preferences to balance active treatment versus early palliative-focused pathway.\",\"oncologist\":\"- Metastatic Krukenberg tumor with brain involvement; systemic therapy now palliative/relapse setting rather than curative.  \\n\\n- Renal function significantly impaired but improving; precise current creatinine, eGFR, and trend needed to choose/regimen-dose systemic therapy.  \\n\\n- No prior systemic therapy lines documented; must confirm any previous chemotherapy, dates, toxicities, and response.  \\n\\n- Biomarkers: HER2-, MSS, low TMB, HRD/BRCA wildtype—targeted/maintenance options limited; PD-L1, CA125, AFP levels unknown/need update.  \\n\\n- Need up-to-date brain and systemic imaging, performance status, and current medications to judge fitness for combination vs less intensive therapy.\",\"radiologist\":\"- Progressive diffuse peritoneal carcinomatosis with omental/mesenteric nodularity and increasing ascites, indicating worsening intra-abdominal disease burden [@IMAGING_STUDIES|2025-02-10].  \\n\\n- Retroperitoneal and pelvic lymphadenopathy consistent with nodal metastases; appears increased compared with earlier CT description [@IMAGING_STUDIES|2025-02-10].  \\n\\n- Bilateral ureteral thickening concerning for potential evolving ureteral obstruction; renal collecting system status unknown/needs update [@IMAGING_STUDIES|2025-02-10].  \\n\\n- Small pleural and peritoneal effusions persist, suggesting ongoing serosal involvement; no large pleural masses described [@IMAGING_STUDIES|2025-01-28].  \\n\\n- Solitary or limited cerebral sulcal metastasis on brain MRI; no trend or hemorrhage information available/needs update [@IMAGING_STUDIES|2025-01-20].\",\"pathologist\":\"- Morphology favors metastatic Krukenberg tumor with mixed mucinous and signet-ring cell features; primary gastrointestinal origin still unconfirmed.  \\n\\n- Extensive involvement of uterine wall, ureter, diaphragm, and lymph nodes indicates widely metastatic disease burden [@HISTOLOGY_AND_IHC|2024-12-20].  \\n\\n- ER/PR negative; no HER2 (ERBB2) amplification, MSS, low TMB, HRD/BRCA wildtype limit certain targeted biomarker options [@HISTOLOGY_AND_IHC|2024-12-20].  \\n\\n- Somatic FBXW7 R505C mutation present; clinical significance here uncertain and should be correlated with GI versus ovarian primary [@HISTOLOGY_AND_IHC|2024-12-20].  \\n\\n- Missing/needs update: detailed primary-site workup reports (upper/lower endoscopy, breast imaging), CA125/AFP, PD-L1 CPS, full panel IHC profile.\",\"nuclear\":\"- Prior PET/CT showed multiple abdominal and pelvic metastases, consistent with disseminated peritoneal and nodal involvement (advanced stage pattern). [@IMAGING_CONTEXT|Unknown]  \\n\\n- Subsequent imaging demonstrates cerebral sulcal metastasis, indicating distant metastatic spread beyond peritoneal cavity. [@IMAGING_CONTEXT|2025-01-20]  \\n\\n- Progressive widespread peritoneal and nodal disease with ascites suggests high whole-abdomen tumor burden. [@IMAGING_CONTEXT|2025-01-28] [@IMAGING_CONTEXT|2025-02-10]  \\n\\n- No current PET/CT report available for this visit; updated whole-body PET/CT report is needed to reassess metabolic disease extent.  \\n\\n- PET would meaningfully refine staging/recurrence suspicion by clarifying active peritoneal, nodal, and distant (e.g., brain) metabolic disease distribution.\"}\n\nOutput:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with extensive peritoneal, nodal, and brain involvement; prognosis poor and management palliative.\n- Morphology and pattern strongly favor metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT, limiting standard targeted/maintenance options.\n- Imaging shows progressive peritoneal carcinomatosis, increasing nodal disease, ascites, and small serosal effusions; cerebral sulcal metastasis present.\n- Renal function impaired but evolving; bilateral ureteral thickening raises concern for obstructive component impacting systemic therapy choices.\n\nControversies:\n- Primary site not yet definitively established (GI vs other), with incomplete primary-site workup documentation.\n- Optimal systemic approach unclear without confirmed prior chemotherapy exposure, current kidney function, and performance status.\n- Role and timing of whole-body PET/CT versus reliance on existing CT/MRI for decision-making.\n- Best CNS strategy (local brain-directed vs systemic with CNS-penetrant regimen) dependent on updated neuroimaging and MDT neuro-oncology/radiation assessment.\n\nMissing Info:\n- Full prior systemic therapy history (regimens, cycles, dates, response, toxicities, platinum exposure).\n- Current renal profile (creatinine, eGFR, trend), degree of obstruction, and urological/nephrology assessment (stents/nephrostomy status).\n- Up-to-date brain MRI and systemic staging, plus ECOG/PS, symptom burden, and current medications.\n- Complete primary-site workup (endoscopy, breast imaging reports), CA125, AFP, PD-L1 CPS, and detailed IHC panel.\n- Recent whole-body PET/CT to reassess metabolic disease extent (if considered useful).\n\nWorking Plan:\n- Clarify prior systemic therapy and obtain updated labs (renal function) and performance status to frame feasible systemic options.\n- Arrange multidisciplinary neuro-oncology/radiation oncology review for brain metastasis management and coordinate with CNS-penetrant systemic strategy, if appropriate.\n- Seek nephrology/urology input on obstructive uropathy, optimization of drainage, and implications for systemic therapy dosing.\n- Complete/obtain missing diagnostic workup (primary-site investigations, biomarkers, updated imaging, possibly PET/CT if available and impactful).\n- Revisit overall goals of care with the patient, integrating prognosis, treatment tolerance, and preferences to balance further active therapy against early palliative-focused care.", "timestamp": "2026-01-17T23:02:14.681903"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with extensive peritoneal, nodal, and brain involvement; prognosis poor and management palliative.\n- Morphology and pattern strongly favor metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT, limiting standard targeted/maintenance options.\n- Imaging shows progressive peritoneal carcinomatosis, increasing nodal disease, ascites, and small serosal effusions; cerebral sulcal metastasis present.\n- Renal function impaired but evolving; bilateral ureteral thickening raises concern for obstructive component impacting systemic therapy choices.\n\nControversies:\n- Primary site not yet definitively established (GI vs other), with incomplete primary-site workup documentation.\n- Optimal systemic approach unclear without confirmed prior chemotherapy exposure, current kidney function, and performance status.\n- Role and timing of whole-body PET/CT versus reliance on existing CT/MRI for decision-making.\n- Best CNS strategy (local brain-directed vs systemic with CNS-penetrant regimen) dependent on updated neuroimaging and MDT neuro-oncology/radiation assessment.\n\nMissing Info:\n- Full prior systemic therapy history (regimens, cycles, dates, response, toxicities, platinum exposure).\n- Current renal profile (creatinine, eGFR, trend), degree of obstruction, and urological/nephrology assessment (stents/nephrostomy status).\n- Up-to-date brain MRI and systemic staging, plus ECOG/PS, symptom burden, and current medications.\n- Complete primary-site workup (endoscopy, breast imaging reports), CA125, AFP, PD-L1 CPS, and detailed IHC panel.\n- Recent whole-body PET/CT to reassess metabolic disease extent (if considered useful).\n\nWorking Plan:\n- Clarify prior systemic therapy and obtain updated labs (renal function) and performance status to frame feasible systemic options.\n- Arrange multidisciplinary neuro-oncology/radiation oncology review for brain metastasis management and coordinate with CNS-penetrant systemic strategy, if appropriate.\n- Seek nephrology/urology input on obstructive uropathy, optimization of drainage, and implications for systemic therapy dosing.\n- Complete/obtain missing diagnostic workup (primary-site investigations, biomarkers, updated imaging, possibly PET/CT if available and impactful).\n- Revisit overall goals of care with the patient, integrating prognosis, treatment tolerance, and preferences to balance further active therapy against early palliative-focused care.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.", "timestamp": "2026-01-17T23:02:18.276423"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with peritoneal, nodal, and brain involvement; prognosis poor, intent palliative.\n- Pattern supports metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal disease, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), impacting systemic therapy feasibility/dosing.\n\nControversies:\n- Primary site not definitively proven (GI vs other) due to incomplete workup.\n- Systemic regimen choice uncertain without full prior treatment history, renal status, and performance status.\n- Added value/timing of PET/CT versus current CT/MRI.\n- Optimal CNS approach (local vs combination with CNS-penetrant systemic therapy) pending specialist input and updated imaging.\n\nMissing Info:\n- Detailed prior systemic therapy (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI, systemic staging, ECOG PS, symptom burden, and medication list.\n- Full primary-site workup (endoscopy, breast imaging), CA125, AFP, PD-L1 CPS, and complete IHC profile.\n- Recent whole-body PET/CT (if deemed clinically useful).\n\nWorking Plan:\n- Confirm prior systemic therapy and update labs (especially renal) and performance status to define palliative systemic options.\n- Arrange neuro-oncology/radiation oncology MDT review for brain metastasis and consider CNS-penetrant systemic strategy.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing constraints.\n- Complete missing diagnostic workup (primary-site evaluation, biomarkers, updated imaging ± PET/CT).\n- Conduct goals-of-care discussion to align further active treatment versus earlier palliative-focused pathway with patient preferences.\n[R1T1 DELTA]  palliative planning. | pathologist->oncologist(missing): Primary remains unproven (GI vs other); extended IHC panel (CDX2, SATB2, CK7/20, PAX8, MUC markers) on available tissue would better define origin and may influence systemic choices. | pathologist->chair(missing): Pathology workup for primary site is incomplete; please confirm whether additional tissue or outside blocks are available for extended IHC to refine primary assignment. | nuclear->oncologist(missing): No recent PET/CT is available; if prognosis and goals permit, a single whole-body PET/CT could clarify current metabolic burden versus CT alone, especially extra-abdominal disease and brain involvement correlation. | nuclear->radiologist(missing): If PET/CT is pursued, please ensure brain-included acquisition and tight coregistration with latest MRI to assess metabolic activity of sulcal lesions and any additional CNS foci.\n[R1T2 DELTA] chair->pathologist(missing): Please confirm availability of existing tissue/blocks and feasibility of extended IHC now, as primary-site assignment may materially affect systemic strategy discussions. | chair->oncologist(safety): Before ordering PET/CT, we should clarify how its results would practically alter systemic or CNS management in a patient already deemed palliative with extensive disease. | radiologist->nuclear(missing): If PET/CT is obtained, please include full head coverage and ensure fusion with the most recent brain MRI for accurate CNS assessment. | radiologist->oncologist(missing): Given prior CT evidence of bilateral ureteral thickening and worsening peritoneal disease, updated contrast-enhanced CT (or MRI) is important to reassess obstruction risk and guide palliative interventions.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Widely metastatic Krukenberg-type mucinous/signet tumor with extensive peritoneal, nodal, and brain disease; prognosis poor, management palliative.\n- Pattern favors metastatic GI primary; ER/PR-, HER2-, MSS, low TMB, HRD/BRCA WT → limited targeted/maintenance options.\n- Imaging shows progressive peritoneal carcinomatosis, nodal progression, ascites, small serosal effusions, and cerebral sulcal metastasis.\n- Renal function impaired with probable obstructive component (bilateral ureteral thickening), constraining systemic therapy dosing/choice.\n\nControversies:\n- Primary site (GI vs other) remains unproven; extended IHC may refine origin and influence systemic strategy.\n- Benefit of PET/CT in a clearly palliative, widely metastatic setting versus CT/MRI alone, and whether results would change management.\n- Optimal CNS approach (local vs combined with CNS-penetrant systemic therapy) pending updated imaging and specialist review.\n\nMissing Info:\n- Full prior systemic therapy details (agents, cycles, dates, response, toxicities, platinum exposure).\n- Current renal function (creatinine, eGFR, trend), degree of obstruction, and urology/nephrology assessment.\n- Updated brain MRI and systemic imaging (including contrast CT/MRI for ureteral/obstruction assessment), ECOG PS, symptoms, and medications.\n- Primary-site workup: availability of tissue/blocks for extended IHC (CDX2, SATB2, CK7/20, PAX8, MUC), plus endoscopy/breast imaging, CA125, AFP, PD-L1 CPS.\n- Decision on and, if chosen, results of any whole-body PET/CT with full head coverage and MRI coregistration.\n\nWorking Plan:\n- Verify prior systemic therapy history and update labs (especially renal) and performance status to frame feasible palliative systemic options.\n- Confirm tissue/block availability and request extended IHC to better define primary site if results would influence systemic decision-making.\n- Arrange neuro-oncology/radiation MDT review for brain metastasis and consider CNS-penetrant systemic strategy where appropriate.\n- Obtain nephrology/urology input on obstructive uropathy, drainage optimization, and chemotherapy dosing limits; repeat contrast-enhanced CT/MRI to reassess obstruction.\n- Decide if PET/CT would meaningfully alter management before ordering; if done, ensure full head coverage and fusion with latest brain MRI.\n- Proceed with structured goals-of-care and palliative planning discussions aligned with prognosis and patient preferences.", "timestamp": "2026-01-17T23:03:26.337028"}]}, "trace_events": [{"ts": "2026-01-17T23:01:33.594891", "event": "pipeline_start", "payload": {"visit_time": "2025-04-03 15:38:50.183000", "meta_info": "130104196909292146"}}, {"ts": "2026-01-17T23:01:33.597070", "event": "case_fingerprint", "payload": {"case_fingerprint": "299dd68c3006"}}, {"ts": "2026-01-17T23:01:33.883607", "event": "reports_loaded", "payload": {"lab_n": 0, "img_n": 0, "path_n": 0, "mut_n": 0, "cutoff_dt": "2025-04-04 15:38:50"}}, {"ts": "2026-01-17T23:01:33.944077", "event": "reports_selected", "payload": {"lab": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "imaging": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "pathology": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "mutation": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}}}, {"ts": "2026-01-17T23:01:51.904876", "event": "rag_query", "payload": {"query": "Metastatic mucinous adenocarcinoma with signet-ring (Krukenberg) of unknown GI primary, platinum‑naïve/unknown; peritoneal, nodal, diaphragm, ureter, and brain metastases; BRCA/HRD‑negative, MSS/TMB‑low; significant obstructive nephropathy with AKI and nephrostomy/stents."}}, {"ts": "2026-01-17T23:01:51.904883", "event": "rag_hits", "payload": {"topk": 5, "n": 5}}, {"ts": "2026-01-17T23:01:56.490675", "event": "mdt_discussion_start", "payload": {"num_rounds": 2, "num_turns": 2}}, {"ts": "2026-01-17T23:04:30.894094", "event": "mdt_discussion_end", "payload": {"merged_chars": 2466}}, {"ts": "2026-01-17T23:04:30.894923", "event": "final_output_start", "payload": {}}, {"ts": "2026-01-17T23:04:34.816802", "event": "final_output_end", "payload": {"final_output_chars": 1459}}], "trace_mermaid": "flowchart TD\n  A[Load Case + Fingerprint] --> B[Load Reports]\n  B --> C[Report Selection per Role]\n  C --> D[Global Guideline RAG]\n  D --> E[Init Specialist Agents]\n  E --> F[MDT Discussion Engine]\n  F --> G[Trial Matching]\n  G --> H[Final Chair Output]\n  H --> I[Save Logs]\n"}
